Nancy J Donovan1, Lauren P Wadsworth2, Natacha Lorius3, Joseph J Locascio2, Dorene M Rentz4, Keith A Johnson5, Reisa A Sperling3, Gad A Marshall3. 1. Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: njdonovan@partners.org. 2. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 3. Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 4. Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 5. Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Abstract
OBJECTIVES: To examine regions of cortical thinning and cerebrospinal fluid (CSF) Alzheimer disease (AD) biomarkers associated with apathy and hallucinations in a continuum of individuals including clinically normal elderly, mild cognitive impairment, and mild AD dementia. DESIGN: Cross-sectional and longitudinal studies. SETTING: Fifty-seven research sites across North America. PARTICIPANTS: Eight-hundred twelve community-dwelling volunteers; 413 participants in the CSF sub-study. MEASUREMENTS: Structural magnetic resonance imaging data and CSF concentrations of amyloid-β 1-42, total tau, and phosphorylated tau derived from the Alzheimer Disease Neuroimaging Initiative database were analyzed. Apathy and hallucinations were measured at baseline and over 3 years using the Neuropsychiatric Inventory-Questionnaire. General linear models and mixed effects models were used to evaluate the relationships among baseline cortical thickness in seven regions, and baseline CSF biomarkers, apathy, and hallucinations at baseline and longitudinally. Covariates included diagnosis, sex, age, apolipoprotein E genotype, premorbid intelligence, memory performance, processing speed, antidepressant use, and AD duration. RESULTS: Reduced baseline inferior temporal cortical thickness was predictive of increasing apathy over time, and reduced supramarginal cortical thickness was predictive of increasing hallucinations over time. There was no association with cortical thickness at baseline. CSF biomarkers were not related to severity of apathy or hallucinations in cross-sectional or longitudinal analyses. CONCLUSIONS: These results suggest that greater baseline temporal and parietal atrophy is associated with worsening apathy and hallucinations in a large AD spectrum cohort, while adjusting for multiple disease-related variables. Localized cortical neurodegeneration may contribute to the pathophysiology of apathy and hallucinations and their adverse consequences in AD.
OBJECTIVES: To examine regions of cortical thinning and cerebrospinal fluid (CSF) Alzheimer disease (AD) biomarkers associated with apathy and hallucinations in a continuum of individuals including clinically normal elderly, mild cognitive impairment, and mild AD dementia. DESIGN: Cross-sectional and longitudinal studies. SETTING: Fifty-seven research sites across North America. PARTICIPANTS: Eight-hundred twelve community-dwelling volunteers; 413 participants in the CSF sub-study. MEASUREMENTS: Structural magnetic resonance imaging data and CSF concentrations of amyloid-β 1-42, total tau, and phosphorylated tau derived from the Alzheimer Disease Neuroimaging Initiative database were analyzed. Apathy and hallucinations were measured at baseline and over 3 years using the Neuropsychiatric Inventory-Questionnaire. General linear models and mixed effects models were used to evaluate the relationships among baseline cortical thickness in seven regions, and baseline CSF biomarkers, apathy, and hallucinations at baseline and longitudinally. Covariates included diagnosis, sex, age, apolipoprotein E genotype, premorbid intelligence, memory performance, processing speed, antidepressant use, and AD duration. RESULTS: Reduced baseline inferior temporal cortical thickness was predictive of increasing apathy over time, and reduced supramarginal cortical thickness was predictive of increasing hallucinations over time. There was no association with cortical thickness at baseline. CSF biomarkers were not related to severity of apathy or hallucinations in cross-sectional or longitudinal analyses. CONCLUSIONS: These results suggest that greater baseline temporal and parietal atrophy is associated with worsening apathy and hallucinations in a large AD spectrum cohort, while adjusting for multiple disease-related variables. Localized cortical neurodegeneration may contribute to the pathophysiology of apathy and hallucinations and their adverse consequences in AD.
Authors: P H Robert; G Darcourt; M P Koulibaly; S Clairet; M Benoit; R Garcia; O Dechaux; J Darcourt Journal: Eur J Neurol Date: 2006-07 Impact factor: 6.089
Authors: Constantine G Lyketsos; Oscar Lopez; Beverly Jones; Annette L Fitzpatrick; John Breitner; Steven DeKosky Journal: JAMA Date: 2002-09-25 Impact factor: 56.272
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Krista L Lanctôt; Shehnaz Moosa; Nathan Herrmann; Farrell S Leibovitch; Lana Rothenburg; Adolfo Cotter; Sandra E Black Journal: Dement Geriatr Cogn Disord Date: 2007-06-11 Impact factor: 2.959
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2017-03-22 Impact factor: 21.566
Authors: Catherine E Munro; Nancy J Donovan; Brendan J Guercio; Sarah E Wigman; Aaron P Schultz; Rebecca E Amariglio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Gad A Marshall Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Ann Kolanowski; Marie Boltz; Elizabeth Galik; Laura N Gitlin; Helen C Kales; Barbara Resnick; Kimberly S Van Haitsma; Amy Knehans; Jane E Sutterlin; Justine S Sefcik; Wen Liu; Darina V Petrovsky; Lauren Massimo; Andrea Gilmore-Bykovskyi; Margaret MacAndrew; Glenna Brewster; Vycki Nalls; Ying-Ling Jao; Naomi Duffort; Danny Scerpella Journal: Nurs Outlook Date: 2017-06-16 Impact factor: 3.250
Authors: Brendan J Guercio; Nancy J Donovan; Catherine E Munro; Sarah L Aghjayan; Sarah E Wigman; Joseph J Locascio; Rebecca E Amariglio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Gad A Marshall Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472